Amgen's accelerating revenue growth (9.7% YoY in Q2 2026) and robust gross margin expansion to 72.0% indicate a favorable product mix shift and strong operational leverage, with EPS surging 64.9% YoY. However, the balance sheet remains strained with $57.3B deb...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 9.7% YoY in Q2 2026 with gross margin expanding to 72.0% from 67.2% a year earlier, driving EPS up 64.9% YoY.
Amgen exceeded revenue and adjusted EPS expectations in Q4 2025, projecting stronger earnings and revenue for 2026.
The company has provided upbeat guidance for 2026, indicating continued growth.
Amgen's late-stage pipeline is expected to drive volume-led growth, particularly with positive Phase 3 data for TEPEZZA.
Amgen faces potential headwinds from upcoming patent expirations for key franchises, impacting future revenue.
Concerns about limited pipeline visibility may necessitate continued business development for sustained growth.
There are growing concerns about global drug pricing efforts that could impact profitability.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $6.29+11.9% vs $5.62 | $10.1B+6.7% vs $9.4B |
Q2 2026 Apr 30, 2026 | $5.15+8.0% vs $4.77 | $8.6B+0.5% vs $8.6B |
Q1 2026 Feb 3, 2026 | $5.29+11.8% vs $4.73 | $9.9B+4.1% vs $9.5B |
Q4 2025 Nov 4, 2025 | $5.64+12.4% vs $5.02 | $9.6B+6.6% vs $9.0B |
Amgen Inc. (NASDAQ:AMGN) has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren's disease accompanied by moderate-to-severe systemic disease activity.
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
Benchmark AMGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amgen Inc. (AMGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $410.24 | $221.41B | 28.83 | 9.92% | 20.99% | 106.1% | 2.3% | |
| $152.67 | $189.55B | 22.52 | 2.39% | -10.64% | -16.35% | — | |
| $225.36 | $33.3B | 25.52 | 1.39% | 8.39% | 4.52% | — | |
| $803.90 | $82.82B | 19.38 | 0.99% | 27.86% | 18.49% | — | |
| $514.99 | $130.71B | 33.62 | 9.57% | 34.89% | 23.31% | — | |
| $62.25 | $127.12B | 18.04 | -0.22% | 18.87% | 46.69% | — |
Amgen Inc. (AMGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amgen Inc. (AMGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 31, 2026·SEC
May 20, 2026·SEC
Get notified when AMGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amgen Inc. (AMGN) stock FAQ — growth, dividends, profitability & financials explained
Amgen Inc. (AMGN) reported $38.13B in revenue for fiscal year 2025. This represents a 1634% increase from $2.20B in 1996.
Amgen Inc. (AMGN) grew revenue by 9.9% over the past year. This is steady growth.
Yes, Amgen Inc. (AMGN) is profitable, generating $8.74B in net income for fiscal year 2025 (21.0% net margin).
Yes, Amgen Inc. (AMGN) pays a dividend with a yield of 2.30%. This makes it attractive for income-focused investors.
Amgen Inc. (AMGN) has a return on equity (ROE) of 106.1%. This is excellent, indicating efficient use of shareholder capital.
Amgen Inc. (AMGN) generated $10.18B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
